Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers.

Détails

ID Serval
serval:BIB_8B6D6344F47A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers.
Périodique
Expert Opinion on Pharmacotherapy
Auteur(s)
Cavassini M.L., D'Acremont V., Furrer H., Genton B., Tarr P.E.
ISSN
1744-7666 (Electronic)
ISSN-L
1465-6566
Statut éditorial
Publié
Date de publication
2005
Volume
6
Numéro
6
Pages
891-913
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
Since the introduction of effective antiretroviral therapy (ART), HIV-infected individuals are travelling more frequently and international travel has become much safer. Specific concerns include the safety of ART during travel, drug adherence and interaction considerations, and effects of immunosuppression. This review describes potentially important infections, vaccine effectiveness, safety and special approaches for their use, and HIV-related issues regarding predeparture counselling. With advanced immunosuppression (CD4+ T-cell count < 200/microl or < 14%), the immunogenicity of several vaccines is reduced, complications could occur after live attenuated vaccines and certain infections acquired during travel may be more frequent or severe. Challenges include the best options for malaria chemoprophylaxis, standby treatment and medical follow-up of the increasing number of HIV-infected long-term travellers.
Mots-clé
Anti-HIV Agents/adverse effects, Anti-HIV Agents/therapeutic use, HIV Infections/complications, HIV Infections/drug therapy, HIV-1, Humans, Malaria/prevention & control, Travel/trends, Vaccines/adverse effects, Vaccines/therapeutic use
Pubmed
Web of science
Création de la notice
28/01/2008 12:49
Dernière modification de la notice
03/03/2018 19:11
Données d'usage